AP NEWS

QIAGEN Launches Novel RNA-Seq Library Preparation Solutions for Next-Generation Sequencing

October 11, 2018

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Oct 11, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a breakthrough technology enabling faster, simpler library preparation for RNA sequencing. A key element of this portfolio is the QIAseq FastSelect RNA Removal Kit which provides a novel solution for scientists to target RNA types that are irrelevant to their research and remove them from RNA-seq libraries for next-generation sequencing (NGS). The global market size for library preparation kits for RNA-seq is believed to be about $400 million.

In addition to a highly competitive and differentiated line of RNA-seq solutions, several other QIAGEN solutions for accurate, efficient NGS will be showcased at ASHG 2018, the conference of the American Society of Human Genetics from October 16-20 in San Diego. In addition, more than 15 studies relying upon QIAseq solutions, the GeneReader NGS System and other QIAGEN Sample to Insight products will be presented in ASHG 2018 scientific sessions, demonstrating the unique positioning of QIAGEN in this rapidly growing market of next generation sequencing.

“The QIAseq FastSelect RNA Removal Kit allows rapid selective removal of RNA classes from any sample, even the most difficult FFPE samples, enabling researchers to attain high quality, reproducible RNA sequencing results while at the same time minimizing time requirements and cost. The QIAseq Fastselect RNA kit can accomplish in one simple workflow step what current RNA sequencing library preparation solutions achieve in over 30 steps. By using a range of proprietary, novel technologies, the QIAseq FastSelect RNA Removal kit therefore radically simplifies and speeds up RNA removal. Off-the-shelf options include rRNA or globin mRNA removal, while custom RNA removal solutions for selected transcripts can be designed by QIAGEN,” said Dr. Thomas Schweins, Senior Vice President of QIAGEN’s Life Sciences Business Area.

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005895/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi, +49 2103 29 11711

Dr. Sarah Fakih, +49 2103 29 11457

ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer, +49 2103 29 11826

Robert Reitze, +49 2103 29 11676

pr@QIAGEN.com

KEYWORD: AUSTRIA UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE

SOURCE: QIAGEN N.V.

Copyright Business Wire 2018.

PUB: 10/11/2018 04:20 PM/DISC: 10/11/2018 04:20 PM

http://www.businesswire.com/news/home/20181011005895/en

AP RADIO
Update hourly